Your patients with clinically low-risk prostate cancer might be candidates for the Oncotype DX Genomic Prostate Score (GPS).
The Oncotype DX GPS assay is for men who have:
- Had a prostate biopsy within the last three years.
- Not started definitive treatment (e.g. surgery or radiation).
- Clinically low-risk prostate cancer (GS 3+3 and 3+4) —meeting the criteria for National Comprehensive Cancer Network (NCCN) very-low, low, or (in select cases) intermediate risk disease.
When to order the test
Because the goal of the Oncotype DX GPS assay is to facilitate management planning for prostate cancer patients, the best time to order the test is shortly after biopsy and before initial treatment decisions have been made. Ordering is easy, and the test can be run on a small sample from a recent biopsy.
Insurance and financial assistance
The Oncotype DX GPS test is covered by Medicare (for NCCN very low or low risk cancer). Private insurance coverage varies. To help patients navigate insurance and other payment options for Oncotype DX testing, Genomic Health offers the Genomic Access Program (GAP). Learn more about insurance coverage and financial assistance by contacting customer service at 866-ONCOTYPE (866-662-6897).